Completed study

Official Study Title
suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial

Brief Description
SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker suPAR. The study ran in 28 study sites in Greece. The results of the interim analysis of the SAVE study were the background for the design of the pivotal phase III study SAVE-MORE.

Status: Active, not recruiting
Study Type: Interventional (Clinical Trial)
Study phase: II
Study sites: 28 sites in Greece
Actual enrolment: 717 participants Identifier: NCT04357366
EudraCT number: 2020-001466-11
National Organization for Medicines Approval: IS028-20
National Ethics Committee Approval: 38/20

Study Start: April 2020
Study Completion:

Condition/Disease studied: COVID-19; Virus Diseases; Corona Virus Infection; Lower Respiratory Tract Infection Viral
Keywords: COVID-19; SARS-CoV-2; anakinra; suPAR

Related publications